Overview

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Status:
Active, not recruiting

Trial end date:
2023-07-01

Target enrollment:

Participant gender:

Summary

This research study is evaluating a combination of two drugs, ibrutinib and obinutuzumab, as a possible treatment for Chronic Lymphocytic Leukemia (CLL).

Phase:

Phase 1

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborator:

Genentech, Inc.

Treatments:

Obinutuzumab